Abound Wealth Management’s Consolidated Edison ED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$560 Sell
5
-28
-85% -$3.04K ﹤0.01% 926
2026
Q1
$3.76K Hold
33
﹤0.01% 795
2025
Q4
$3.3K Buy
33
+2
+6% +$198 ﹤0.01% 763
2025
Q3
$3.13K Hold
31
﹤0.01% 737
2025
Q2
$3.13K Sell
31
-2
-6% -$212 ﹤0.01% 675
2025
Q1
$3.67K Sell
33
-59
-64% -$5.79K ﹤0.01% 598
2024
Q4
$8.22K Buy
92
+1
+1% +$98 ﹤0.01% 430
2024
Q3
$9.49K Buy
91
+6
+7% +$593 ﹤0.01% 424
2024
Q2
$7.61K Hold
85
﹤0.01% 413
2024
Q1
$7.73K Sell
85
-270
-76% -$24.2K ﹤0.01% 426
2023
Q4
$32.3K Buy
355
+164
+86% +$14.7K 0.01% 193
2023
Q3
$16.3K Sell
191
-3
-2% -$273 0.01% 242
2023
Q2
$17.5K Buy
194
+8
+4% +$765 0.01% 234
2023
Q1
$17.8K Buy
186
+34
+22% +$3.18K 0.01% 221
2022
Q4
$14.5K Buy
152
+1
+0.7% +$91 0.01% 222
2022
Q3
$13K Buy
+151
New +$14.6K 0.01% 251

Other funds holding ED

Abound Wealth Management's ED Position: Q2 2026 in Review

Abound Wealth Management reduced its Consolidated Edison (ED) stake by 85% in Q2 2026, selling an estimated $3.04K and leaving 5 shares worth $560. The position accounts for ﹤0.01% of the portfolio, ranked #926.

Abound Wealth Management first reported a position in ED in Q3 2022 and has held it in 16 quarters since. The position peaked at $32.3K in Q4 2023. 1,421 funds tracked by Wall St. Rank hold ED as of Q2 2026.

  • Abound Wealth Management held 5 shares of Consolidated Edison worth $560 as of Q2 2026.
  • Abound Wealth Management sold 28 Consolidated Edison shares in Q2 2026, an estimated $3.04K.
  • Consolidated Edison made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #926 holding.
  • Abound Wealth Management first reported a position in Consolidated Edison in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's Consolidated Edison position peaked at $32.3K in Q4 2023.
  • 1,421 funds tracked by Wall St. Rank held Consolidated Edison as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.